| Symbol | VIR |
|---|---|
| Name | VIR BIOTECHNOLOGY, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 499 ILLINOIS STREET,SUITE 500, SAN FRANCISCO, California, 94158, United States |
| Telephone | +1 415 906-4324 |
| Fax | — |
| — | |
| Website | https://www.vir.bio |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001706431 |
| Description | Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The companys pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. Additional info from NASDAQ: |
2026-08-25 15:07
📋 O'Byrne Jason (Ex-Officer) plans to sell 23K shares of Vir Biotechnology, Inc. (at $10.48 each, total $243K) Filed: Aug 25, 2026 | ID: 006425
Read more
2026-08-24 21:11
📋 O'Byrne Jason (Ex-Officer) plans to sell 14K shares of Vir Biotechnology, Inc. (at $9.90 each, total $142K) Filed: Aug 24, 2026 | ID: 006413
Read more
2026-08-21 19:24
📋 O'Byrne Jason (Ex-Officer) plans to sell 25K shares of Vir Biotechnology, Inc. (at $9.81 each, total $245K) Filed: Aug 21, 2026 | ID: 006329
Read more
2026-08-07 12:11
New Form SCHEDULE 13G - Vir Biotechnology, Inc. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000093751-26-000556 <b>Size:</b> 8 KB
Read more
2026-08-05 20:05
Vir Biotechnology - Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Read more
2026-08-05 20:05
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Read more
2026-07-31 12:40
New Form SCHEDULE 13G/A - Vir Biotechnology, Inc. <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0002100121-26-000992 <b>Size:</b> 7 KB
Read more
2026-07-24 12:31
(99% Neutral) VIR BIOTECHNOLOGY, INC. (VIR) Announces New Board Appointment
Read more
2026-07-24 12:30
Vir Biotechnology - Vir Biotechnology Announces Chief Financial Officer Transition
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05235347 | Sotrovimab Expanded Access Treatment Protocol (COVID-19) | — | Covid19 | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07142811 | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infe… | Phase2 | Viral Hepatitis | Active_Not_Recruiting | 2025-08-05 | 2030-07-01 | ClinicalTrials.gov |
| NCT07128550 | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infec… | Phase3 | Viral Hepatitis | Recruiting | 2025-07-30 | 2031-07-01 | ClinicalTrials.gov |
| NCT06960395 | Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Par… | Phase1 | Solid Tumor Malignancies | Recruiting | 2025-07-22 | 2029-08-01 | ClinicalTrials.gov |
| NCT06903338 | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | Phase3 | Viral Hepatitis | Active_Not_Recruiting | 2025-03-12 | 2031-05-01 | ClinicalTrials.gov |
| NCT06491563 | Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, B… | Phase2 | For Treatment of Chronic Hepatitis B Virus Infection | Active_Not_Recruiting | 2024-08-06 | 2027-06-01 | ClinicalTrials.gov |
| NCT06070051 | Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral… | Phase1 | Chronic Hepatitis B | Completed | 2023-09-26 | 2026-03-31 | ClinicalTrials.gov |
| NCT05970289 | Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combina… | Phase2 | Chronic Hepatitis B Virus Infection | Active_Not_Recruiting | 2023-08-22 | 2026-02-01 | ClinicalTrials.gov |
| NCT05844228 | A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics a… | Phase1 | Renal Impairment | Completed | 2023-06-01 | 2025-04-21 | ClinicalTrials.gov |
| NCT05612581 | A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B I… | Phase1 | Hepatitis B, Chronic | Completed | 2023-05-10 | 2025-08-19 | ClinicalTrials.gov |
| NCT05567783 | A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevent… | Phase2 | Influenza A | Terminated | 2022-10-30 | 2023-08-31 | ClinicalTrials.gov |
| NCT05484206 | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and… | Phase1 | Hepatic Impairment | Recruiting | 2022-09-21 | 2027-04-30 | ClinicalTrials.gov |
| NCT05461170 | SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infectio… | Phase2 | Hepatitis D, Chronic | Active_Not_Recruiting | 2022-09-17 | 2032-05-01 | ClinicalTrials.gov |
| NCT05356741 | To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alon… | Phase1 | Locally Advanced or Metastatic HER2-Expressing Cancers | Recruiting | 2022-04-13 | 2028-04-01 | ClinicalTrials.gov |
| NCT05280717 | Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab In… | Phase1 | Covid19 | Terminated | 2022-03-28 | 2023-11-06 | ClinicalTrials.gov |
| NCT05135650 | Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hema… | Phase1 | COVID-19 Infection | Terminated | 2022-01-25 | 2023-01-10 | ClinicalTrials.gov |
| NCT05124210 | Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in Hig… | Phase2 | COVID-19 | Terminated | 2021-12-16 | 2023-06-14 | ClinicalTrials.gov |
| NCT04891770 | Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Co… | Phase2 | Chronic Hepatitis B | Completed | 2021-08-14 | 2024-07-19 | ClinicalTrials.gov |
| NCT04856085 | Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis… | Phase2 | Hepatitis B, Chronic | Completed | 2021-07-11 | 2026-03-16 | ClinicalTrials.gov |
| NCT04988152 | A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placeb… | Phase1 | Covid19 | Completed | 2021-07-06 | 2021-12-07 | ClinicalTrials.gov |
| NCT04913675 | Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. | Phase3 | Covid19 | Terminated | 2021-06-10 | 2023-03-24 | ClinicalTrials.gov |
| NCT04749368 | Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combinati… | Phase2 | Hepatitis B, Chronic | Completed | 2021-04-12 | 2023-07-04 | ClinicalTrials.gov |
| NCT04779879 | Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Materia… | Phase2 | Covid19 | Completed | 2021-02-18 | 2022-04-06 | ClinicalTrials.gov |
| NCT04725877 | VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus … | Phase1 | HIV I Infection | Completed | 2020-12-28 | 2022-12-05 | ClinicalTrials.gov |
| NCT05780281 | VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) | Phase3 | COVID-19 | Completed | 2020-12-16 | 2022-10-04 | ClinicalTrials.gov |
| NCT04545060 | VIR-7831 for the Early Treatment of COVID-19 in Outpatients | Phase2 | Covid19 | Completed | 2020-08-27 | 2021-09-02 | ClinicalTrials.gov |
| NCT04507269 | Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China | Phase2 | Hepatitis B, Chronic | Completed | 2020-08-18 | 2021-09-30 | ClinicalTrials.gov |
| NCT04412863 | Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment o… | Phase2 | Chronic Hepatitis B | Completed | 2020-07-03 | 2024-03-25 | ClinicalTrials.gov |
| NCT04423393 | Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B V… | Phase1 | Chronic Hepatitis B | Completed | 2020-05-26 | 2022-11-25 | ClinicalTrials.gov |
| NCT04033406 | Study of VIR-2482 in Healthy Volunteers | Phase1 | Influenza A | Completed | 2019-08-26 | 2021-11-01 | ClinicalTrials.gov |
| NCT03672188 | Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B | Phase1 | Chronic Hepatitis B | Completed | 2018-11-14 | 2020-09-03 | ClinicalTrials.gov |
Total clinical trials: 31
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| VIR-3434 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT06070051 |
| VIR-2218 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT06070051 |
| VRON-0200-AdC7 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT06070051 |
| VRON-0200-AdC6 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT06070051 |
| pembrolizumab | Other | Phase PHASE1 | Locally Advanced or Metastatic HER2-Expressing Cancers | RECRUITING | NCT05356741 |
| VIR-5818 | Other | Phase PHASE1 | Locally Advanced or Metastatic HER2-Expressing Cancers | RECRUITING | NCT05356741 |
| BRII-179 (VBI-2601) | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04749368 |
| BRII-179 (VBI-2601) with IFN-α | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04749368 |
| BRII-835 (VIR-2218) | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04749368 |
| NRTI | Other | Phase PHASE2 | Hepatitis D, Chronic | ACTIVE_NOT_RECRUITING | NCT05461170 |
| VIR-3434 | Other | Phase PHASE2 | Hepatitis D, Chronic | ACTIVE_NOT_RECRUITING | NCT05461170 |
| VIR-2218 | Other | Phase PHASE2 | Hepatitis D, Chronic | ACTIVE_NOT_RECRUITING | NCT05461170 |
| ARSI | Other | Phase PHASE1 | Hormone-refractory Prostate Cancer | RECRUITING | NCT05997615 |
| VIR-5500 | Other | Phase PHASE1 | Hormone-refractory Prostate Cancer | RECRUITING | NCT05997615 |
| Bulevirtide | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Elebsiran | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Tobevibart | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Bulevirtide | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Elebsiran | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Tobevibart | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Bulevirtide | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Elebsiran | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Tobevibart | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Bulevirtide | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Elebsiran | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Tobevibart | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Bulevirtide | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Elebsiran | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Tobevibart | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Bulevirtide | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Elebsiran | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Tobevibart | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Bulevirtide | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Elebsiran | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Tobevibart | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Bulevirtide | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Elebsiran | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Tobevibart | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Bulevirtide | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Elebsiran | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Tobevibart | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Placebo | Other | Phase PHASE1 | Influenza A | COMPLETED | NCT04033406 |
| VIR-2482 | Other | Phase PHASE1 | Influenza A | COMPLETED | NCT04033406 |
| Remdesivir | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05780281 |
| Placebo | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05780281 |
| VIR-7831 | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05780281 |
| sotrovimab | Other | Phase PHASE1 | Covid19 | TERMINATED | NCT05280717 |
| Biospecimen Collection | Other | Phase PHASE1 | COVID-19 Infection | TERMINATED | NCT05135650 |
| Sotrovimab | Other | Phase PHASE1 | COVID-19 Infection | TERMINATED | NCT05135650 |
| Questionnaire Administration | Other | Phase PHASE1 | COVID-19 Infection | TERMINATED | NCT05135650 |
| Selgantolimod | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04891770 |
| Nivolumab | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04891770 |
| VIR-2218 | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04891770 |
| Tenofovir Alafenamide | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04891770 |
| Placebo | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT03672188 |
| VIR-2218 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT03672188 |
| Placebo | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04545060 |
| VIR-7831 (sotrovimab) | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04545060 |
| Sotrovimab | Other | Preclinical | Covid19 | NO_LONGER_AVAILABLE | NCT05235347 |
| Placebo | Other | Phase PHASE1 | HIV I Infection | COMPLETED | NCT04725877 |
| VIR-1111 | Other | Phase PHASE1 | HIV I Infection | COMPLETED | NCT04725877 |
| Sotrovimab (Gen2) | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04779879 |
| Sotrovimab (Gen1) | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04779879 |
| Sotrovimab | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT05124210 |
| Sotrovimab | Other | Phase PHASE3 | Covid19 | TERMINATED | NCT04913675 |
| sotrovimab | Other | Phase PHASE3 | Covid19 | TERMINATED | NCT04913675 |
| Placebo to Biologic | Other | Phase PHASE1 | Covid19 | COMPLETED | NCT04988152 |
| sotrovimab | Other | Phase PHASE1 | Covid19 | COMPLETED | NCT04988152 |
| BRII-179 (VBI-2601) | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04749368 |
| BRII-179 (VBI-2601) with IFN-α | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04749368 |
| BRII-835 (VIR-2218) | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04749368 |
| Placebo | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04507269 |
| VIR-2218 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04507269 |
| Placebo | Other | Phase PHASE2 | Influenza A | TERMINATED | NCT05567783 |
| VIR-2482 (1200 mg) | Other | Phase PHASE2 | Influenza A | TERMINATED | NCT05567783 |
| VIR-2482 (450 mg) | Other | Phase PHASE2 | Influenza A | TERMINATED | NCT05567783 |
| Placebo | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04423393 |
| VIR-3434 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04423393 |
| PEG-IFNα | Other | Phase PHASE2 | For Treatment of Chronic Hepatitis B Virus Infection | ACTIVE_NOT_RECRUITING | NCT06491563 |
| BRII-835 (VIR-2218) | Other | Phase PHASE2 | For Treatment of Chronic Hepatitis B Virus Infection | ACTIVE_NOT_RECRUITING | NCT06491563 |
| BRII-179 | Other | Phase PHASE2 | For Treatment of Chronic Hepatitis B Virus Infection | ACTIVE_NOT_RECRUITING | NCT06491563 |
| VIR-3434 | Other | Phase PHASE1 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT06070051 |
| VIR-2218 | Other | Phase PHASE1 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT06070051 |
| VRON-0200-AdC7 | Other | Phase PHASE1 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT06070051 |
| VRON-0200-AdC6 | Other | Phase PHASE1 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT06070051 |
| VIR-2218 | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT05844228 |
| VIR-3434 | Other | Phase PHASE1 | Hepatic Impairment | RECRUITING | NCT05484206 |
| VIR-2218 | Other | Phase PHASE1 | Hepatic Impairment | RECRUITING | NCT05484206 |
| BRII-835 | Other | Phase PHASE2 | Chronic Hepatitis B Virus Infection | ACTIVE_NOT_RECRUITING | NCT05970289 |
| PEG-IFNα | Other | Phase PHASE2 | Chronic Hepatitis B Virus Infection | ACTIVE_NOT_RECRUITING | NCT05970289 |
| pembrolizumab | Other | Phase PHASE1 | Locally Advanced or Metastatic HER2-Expressing Cancers | RECRUITING | NCT05356741 |
| VIR-5818 | Other | Phase PHASE1 | Locally Advanced or Metastatic HER2-Expressing Cancers | RECRUITING | NCT05356741 |
| Bulevirtide | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Elebsiran | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| Tobevibart | Other | Phase PHASE3 | Viral Hepatitis | RECRUITING | NCT07128550 |
| NRTI | Other | Phase PHASE2 | Hepatitis D, Chronic | ACTIVE_NOT_RECRUITING | NCT05461170 |
| VIR-3434 | Other | Phase PHASE2 | Hepatitis D, Chronic | ACTIVE_NOT_RECRUITING | NCT05461170 |
| VIR-2218 | Other | Phase PHASE2 | Hepatitis D, Chronic | ACTIVE_NOT_RECRUITING | NCT05461170 |
| Bulevirtide | Other | Phase PHASE2 | Viral Hepatitis | ACTIVE_NOT_RECRUITING | NCT07142811 |
| Elebsiran | Other | Phase PHASE2 | Viral Hepatitis | ACTIVE_NOT_RECRUITING | NCT07142811 |
| Tobevibart | Other | Phase PHASE2 | Viral Hepatitis | ACTIVE_NOT_RECRUITING | NCT07142811 |
| PEG-IFNα | Other | Phase PHASE1 | Hepatitis B, Chronic | COMPLETED | NCT05612581 |
| TDF | Other | Phase PHASE1 | Hepatitis B, Chronic | COMPLETED | NCT05612581 |
| VIR-2218 | Other | Phase PHASE1 | Hepatitis B, Chronic | COMPLETED | NCT05612581 |
| VIR-3434 | Other | Phase PHASE1 | Hepatitis B, Chronic | COMPLETED | NCT05612581 |
| Elebsiran | Other | Phase PHASE3 | Viral Hepatitis | ACTIVE_NOT_RECRUITING | NCT06903338 |
| Tobevibart | Other | Phase PHASE3 | Viral Hepatitis | ACTIVE_NOT_RECRUITING | NCT06903338 |
| Pembrolizumab | Other | Phase PHASE1 | Solid Tumor Malignancies | RECRUITING | NCT06960395 |
| VIR-5525 | Other | Phase PHASE1 | Solid Tumor Malignancies | RECRUITING | NCT06960395 |
| pegylated interferon-alfa 2a | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04412863 |
| VIR-2218 | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04412863 |
| Darolutamide | Other | Phase PHASE1 | Hormone-refractory Prostate Cancer | RECRUITING | NCT05997615 |
| Enzalutamide | Other | Phase PHASE1 | Hormone-refractory Prostate Cancer | RECRUITING | NCT05997615 |
| VIR-5500 | Other | Phase PHASE1 | Hormone-refractory Prostate Cancer | RECRUITING | NCT05997615 |
| PEG-IFNα | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-3434 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-2218 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| PEG-IFNα | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-3434 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-2218 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| PEG-IFNα | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-3434 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-2218 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| PEG-IFNα | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-3434 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-2218 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| PEG-IFNα | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-3434 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-2218 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| PEG-IFNα | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-3434 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-2218 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| PEG-IFNα | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-3434 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-2218 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| PEG-IFNα | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-3434 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-2218 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| PEG-IFNα | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-3434 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-2218 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| PEG-IFNα | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-3434 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-2218 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| PEG-IFNα | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-3434 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-2218 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| PEG-IFNα | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-3434 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| VIR-2218 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04856085 |
| pegylated interferon-alfa 2a | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04412863 |
| VIR-2218 | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04412863 |
| pegylated interferon-alfa 2a | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04412863 |
| VIR-2218 | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04412863 |
| pegylated interferon-alfa 2a | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04412863 |
| VIR-2218 | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04412863 |
| AC-201, 75mg | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01276106 |
| AC-201, 50mg | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01276106 |
| AC-201, 25mg | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01276106 |
| Ranpirnase | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | WITHDRAWN | NCT01184287 |
| Clobetasol 0.05% Topical Ointment | DRUG | Phase PHASE2 | Bullous Pemphigoid | TERMINATED | NCT03286582 |
| AC-203 1% Topical Ointment | DRUG | Phase PHASE2 | Bullous Pemphigoid | TERMINATED | NCT03286582 |
| AC-201CR | DRUG | Phase PHASE2 | Hemophilic Arthropathy | COMPLETED | NCT02994147 |
| Tofacitinib Citrate | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04468425 |
| Placebo Gel | OTHER | Phase PHASE2 | EGFR Inhibitor-Induced Skin Rash | COMPLETED | NCT04239846 |
| AC-701 Topical Gel 0.3% | DRUG | Phase PHASE2 | EGFR Inhibitor-Induced Skin Rash | COMPLETED | NCT04239846 |
| Febuxostat | DRUG | Phase PHASE2 | Gout Flares | COMPLETED | NCT01712204 |
| AC-201 | DRUG | Phase PHASE2 | Gout Flares | COMPLETED | NCT01712204 |
| AC-1101 | DRUG | Phase PHASE1 | Granuloma Annulare | COMPLETED | NCT05580042 |
| Proton pump inhibitor | DRUG | Preclinical | Glioblastoma | AVAILABLE | NCT05974410 |
| Hydrocortisone | DRUG | Preclinical | Glioblastoma | AVAILABLE | NCT05974410 |
| AVM0703 | DRUG | Preclinical | Glioblastoma | AVAILABLE | NCT05974410 |
| Vehicle | DRUG | Phase PHASE1 | Condylomata Acuminata | COMPLETED | NCT02535104 |
| AC-203 | DRUG | Phase PHASE2 | Inherited Epidermolysis Bullosa | COMPLETED | NCT03468322 |
| Bulevirtide | DRUG | Phase PHASE2 | Viral Hepatitis | ACTIVE_NOT_RECRUITING | NCT07142811 |
| Pembrolizumab | DRUG | Phase PHASE1 | Solid Tumor Malignancies | RECRUITING | NCT06960395 |
| VIR-5525 | DRUG | Phase PHASE1 | Solid Tumor Malignancies | RECRUITING | NCT06960395 |
| Elebsiran | DRUG | Phase PHASE3 | Viral Hepatitis | ACTIVE_NOT_RECRUITING | NCT06903338 |
| Tobevibart | DRUG | Phase PHASE3 | Viral Hepatitis | ACTIVE_NOT_RECRUITING | NCT06903338 |
| BRII-179 | BIOLOGICAL | Phase PHASE2 | For Treatment of Chronic Hepatitis B Virus Infection | ACTIVE_NOT_RECRUITING | NCT06491563 |
| VRON-0200-AdC7 | BIOLOGICAL | Phase PHASE1 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT06070051 |
| VRON-0200-AdC6 | BIOLOGICAL | Phase PHASE1 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT06070051 |
| VIR-5500 | DRUG | Phase PHASE1 | Hormone-refractory Prostate Cancer | RECRUITING | NCT05997615 |
| BRII-835 | DRUG | Phase PHASE2 | Chronic Hepatitis B Virus Infection | ACTIVE_NOT_RECRUITING | NCT05970289 |
| VIR-1388 | BIOLOGICAL | Phase PHASE1 | HIV I Infection | ACTIVE_NOT_RECRUITING | NCT05854381 |
| Remdesivir | BIOLOGICAL | Phase PHASE3 | COVID-19 | COMPLETED | NCT05780281 |
| VIR-7831 | BIOLOGICAL | Phase PHASE3 | COVID-19 | COMPLETED | NCT05780281 |
| TDF | DRUG | Phase PHASE1 | Hepatitis B, Chronic | COMPLETED | NCT05612581 |
| VIR-2482 (1200 mg) | BIOLOGICAL | Phase PHASE2 | Influenza A | TERMINATED | NCT05567783 |
| VIR-2482 (450 mg) | BIOLOGICAL | Phase PHASE2 | Influenza A | TERMINATED | NCT05567783 |
| NRTI | DRUG | Phase PHASE2 | Hepatitis D, Chronic | ACTIVE_NOT_RECRUITING | NCT05461170 |
| pembrolizumab | DRUG | Phase PHASE1 | Locally Advanced or Metastatic HER2-Expressing Cancers | RECRUITING | NCT05356741 |
| VIR-5818 | DRUG | Phase PHASE1 | Locally Advanced or Metastatic HER2-Expressing Cancers | RECRUITING | NCT05356741 |
| Biospecimen Collection | PROCEDURE | Phase PHASE1 | COVID-19 Infection | TERMINATED | NCT05135650 |
| Questionnaire Administration | OTHER | Phase PHASE1 | COVID-19 Infection | TERMINATED | NCT05135650 |
| Placebo to Biologic | OTHER | Phase PHASE1 | Covid19 | COMPLETED | NCT04988152 |
| Sotrovimab | BIOLOGICAL | Preclinical | Covid19 | NO_LONGER_AVAILABLE | NCT05235347 |
| sotrovimab | BIOLOGICAL | Phase PHASE1 | Covid19 | TERMINATED | NCT05280717 |
| Selgantolimod | DRUG | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04891770 |
| Nivolumab | DRUG | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04891770 |
| Tenofovir Alafenamide | DRUG | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04891770 |
| PEG-IFNα | BIOLOGICAL | Phase PHASE2 | For Treatment of Chronic Hepatitis B Virus Infection | ACTIVE_NOT_RECRUITING | NCT06491563 |
| Sotrovimab (Gen2) | BIOLOGICAL | Phase PHASE2 | Covid19 | COMPLETED | NCT04779879 |
| Sotrovimab (Gen1) | BIOLOGICAL | Phase PHASE2 | Covid19 | COMPLETED | NCT04779879 |
| BRII-179 (VBI-2601) | BIOLOGICAL | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04749368 |
| BRII-179 (VBI-2601) with IFN-α | BIOLOGICAL | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT04749368 |
| BRII-835 (VIR-2218) | DRUG | Phase PHASE2 | For Treatment of Chronic Hepatitis B Virus Infection | ACTIVE_NOT_RECRUITING | NCT06491563 |
| VIR-1111 | BIOLOGICAL | Phase PHASE1 | HIV I Infection | COMPLETED | NCT04725877 |
| VIR-7831 (sotrovimab) | BIOLOGICAL | Phase PHASE2 | Covid19 | COMPLETED | NCT04545060 |
| VIR-3434 | DRUG | Phase PHASE1 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT06070051 |
| pegylated interferon-alfa 2a | DRUG | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT04412863 |
| VIR-2482 | DRUG | Phase PHASE1 | Influenza A | COMPLETED | NCT04033406 |
| Placebo | DRUG | Phase PHASE2 | Gout Flares | COMPLETED | NCT01712204 |
| VIR-2218 | DRUG | Phase PHASE1 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT06070051 |
Total products: 214